CENTRE INITIATES PROBE AGAINST RAW MATERIAL DUMPING BY CHINESE FIRMS
India has initiated a probe into alleged dumping of a pharma raw material, Ceftriaxone Sodium Sterile, from China, following complaints by domestic manufacturers.
Nectar Life Sciences and Sterile India have filed an application before the commerce ministry’s investigation arm Directorate General of Trade Remedies (DGTR) seeking initiation of the probe.
According to a DGTR notification, the applicants have contended that material injury is being caused to the domestic industry due to dumped imports from China.
They requested imposition of anti-dumping duty on the import.
Ceftriaxone Sodium Sterile is an active pharmaceutical ingredient (API) or raw material used for formulation for treating disease like lower respiratory tract infection, skin infection, and intra-abdominal infection.
“On the basis of the duly substantiated written application by the domestic industry, and having satisfied itself, on the basis of the prima facie evidence submitted by the domestic industry, about dumping of the subject goods originating in or exported from the subject country (China)...the authority, hereby, initiates an investigation,” it said.
In the probe, the directorate will determine the existence, degree and effect of alleged dumping in respect of the product from China.
If DGTR finds that there is dumping of the product which is impacting domestic manufacturers, it will recommend the amount of anti-dumping duty, which if levied, would be adequate to remove the injury to the domestic industry.
While DGTR recommends the duty, the finance ministry imposes it.
The period of investigation is April 2019-March 2020. It would also look into the data of April 2016-19 period.